Text Size

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

This study has been completed.
Sponsor:
Collaborators:
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Rambam Health Care Campus
Information provided by (Responsible Party):
David Avigan, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00458653
First received: April 10, 2007
Last updated: June 14, 2012
Last verified: June 2012
History of Changes

April 10, 2007
June 14, 2012
April 2005
April 2012   (final data collection date for primary outcome measure)
To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.
Complete list of historical versions of study NCT00458653 on ClinicalTrials.gov Archive Site
  • To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To determine the time to disease progression in this participant population. [ Time Frame: TBD ] [ Designated as safety issue: No ]
  • To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue
  • to determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant
  • to determine the time to disease progression in this participant population.
Not Provided
Not Provided
 
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma

The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for patients with multiple myeloma. Autologous stem cell transplantation is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer. However, it is not a cure because at some point the multiple myeloma generally begins to grow again. Cancer vaccines are investigational agents that try to stimulate the immune system to recognize and fight against cancer cells. One type of cancer vaccine uses an immune stimulating cell of the body known as a dendritic cell. Research has shown that these dendritic cells can stimulate an immune response against the tumor.
  • The first group of participants on this study will receive up to 3 monthly doses of the study vaccine beginning about 1 month following the autologous transplant. If this is found to be safe, the next group will receive one additional study vaccine prior to the transplant and then up to 3 doses after the transplant.
  • If the screening tests determine that the participant is eligible for the study, they will undergo dendritic cell collection by a procedure called leukapheresis. Leukapheresis involves the collection of white blood cells from the blood. Dendritic cells are grown from these white blood cells in the laboratory. Tumor cells will also be collected from the bone marrow through a bone marrow aspirate/biopsy.
  • After cells have been collected for study vaccine generation, the participant may receive standard therapy to reduce the number of multiple myeloma cells in the body. The specific regimen will be determined by the participants multiple myeloma physician.
  • The first group of patients will receive the study vaccine only after the transplant. If this is found safe then the second group will receive a single study vaccine prior to the transplant.
  • Prior to the autologous stem cell transplant, we will harvest stem cells from the participants blood that will be used for the transplant later. G-CSF will be given as a daily injection beginning the day after the chemotherapy and GM-CSF injections will be started seven days after the chemotherapy. These injections will continue until after the stem cells are collected. Approximately 10 days after the chemotherapy, participants will undergo a leukapheresis procedure to collect the stem cells.
  • Within a few weeks of successful stem cell collection, the participant will be admitted to the hospital for high dose chemotherapy with autologous stem cell transplantation.
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Biological: Dendritic Cell Tumor Fusion

Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.

Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT
  • Experimental: Group A
    Post-transplant vaccination
    Intervention: Biological: Dendritic Cell Tumor Fusion
  • Experimental: Group B
    Pre- and post-transplant vaccination
    Intervention: Biological: Dendritic Cell Tumor Fusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with multiple myeloma who are potential candidates for high dose chemotherapy
  • Measurable disease as defined by a history of an elevated M component in plasma, urine, or free kappa/lambda light chains in the serum
  • 18 years of age or older
  • ECOG Performance Status of 0-1 with greater than a nine week life expectancy
  • Patients with > 20% bone marrow involvement or plasmacytoma amenable to resection under local anesthesia
  • Negative pregnancy test, and adequate contraception method
  • DLCO (adjusted)> 50%
  • Cardiac Ejection Fraction > 45%
  • Laboratory values within the ranges outlined in the protocol

Exclusion Criteria:

  • History of clinically significant venous thromboembolism
  • Clinically significant autoimmune disease
  • HIV positive
  • Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Pregnant or lactating women
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Israel
 
NCT00458653
04-098
Yes
David Avigan, MD, Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Rambam Health Care Campus
Principal Investigator: David Avigan, MD Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP